It is an amazing report. I think hottod will find it so. Salient points are as follows. 1/ 30c valuation, up from 24c purely because of the extra (renal)asset. 2/ a comparison with NEU from 2012 when the companies had similar assets/prospects. i think PYC’s timelines are much reduced to NEU’s ( 3yrs vs 9) 3/ an expected uplift in PYC share price if the RP11 asset passes safety and gets some early efficacy data readouts…. That takes the fair price to 54c possibly sometime next year…. Hmm. 4/a lot of the same info that PYC released 5/comparisons with many other biotech/pharmas many of whom have crazy valuations. One or two over 50B US. I think the message is that we have a similar path open to us should all this pan out the way it looks like it will.
Dont sell.
PYC Price at posting:
7.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)